Recognizing that radioligand therapy is most effective early when tumors are "target-rich," new clinical trials accelerate dosing and intensity upfront. This strategy aims to deliver the most significant therapeutic blow before diminishing returns set in as the tumor responds and the target is lost.

The JCOG 1008 trial exclusively studied cisplatin-eligible patients. Therefore, the weekly regimen should be seen as an alternative schedule for those who can tolerate cisplatin, not as a less toxic option to enable treatment for patients who are truly ineligible due to poor renal function, hearing loss, or other comorbidities.

Due to cumulative toxicity concerns with TDXD, particularly ILD, clinicians express more comfort with the shorter 4-cycle neoadjuvant course from DESTINY-Breast11 than the prolonged 14-cycle adjuvant therapy in DESTINY-Breast05, favoring front-loading the treatment.

Instead of starting all three drugs in a triplet combination simultaneously, a more effective clinical approach is to introduce them sequentially. By starting one drug, then adding the second, and finally the third over a period of weeks or months, clinicians can more easily identify the source of any toxicities, leading to better management and improved patient compliance.

Despite logistical challenges like clinic chair time, the ICON 8B study's positive results are forcing a re-evaluation of weekly paclitaxel. The trial demonstrated improved progression-free and overall survival compared to the standard three-week cycle, suggesting a potential shift back to a previously debated dose-dense strategy in the frontline setting.

The JCOG 1008 trial defined treatment completion as receiving at least five of seven planned weekly cisplatin doses (200 mg/m²). This provides clinicians with a practical, data-supported minimum target when managing patient toxicity, helping to balance efficacy against the need to push for all seven doses.

The ERA SAFE study found that a bi-weekly, lower-dose docetaxel regimen for triplet therapy significantly lowers grade 3-4 adverse events compared to the standard 3-week schedule. It reduced the risk of neutropenic fever from 5.5% to 1.7% while maintaining similar efficacy, offering a safer alternative for frail or vulnerable patients.

Clinicians emphasize that maintaining treatment continuity with a reduced, tolerable chemotherapy dose is superior to discontinuing therapy due to side effects. This approach helps patients stay on treatment longer, potentially improving overall survival.

New bladder-sparing trials mandate nine cycles of EV-Pembro to replicate the conditions of successful surgical trials. This conservative approach ignores that patient response is front-loaded while toxicity is back-loaded, likely overtreating many patients to ensure comparable efficacy.